Tri Locum Partners LP Takes $4.62 Million Position in LivaNova PLC (NASDAQ:LIVN)

Tri Locum Partners LP acquired a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 99,700 shares of the company's stock, valued at approximately $4,617,000. LivaNova accounts for 1.0% of Tri Locum Partners LP's investment portfolio, making the stock its 26th biggest position. Tri Locum Partners LP owned about 0.18% of LivaNova as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Russell Investments Group Ltd. lifted its position in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after acquiring an additional 219 shares during the period. Sterling Capital Management LLC lifted its holdings in shares of LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after purchasing an additional 1,441 shares during the period. Central Pacific Bank Trust Division grew its position in LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after buying an additional 720 shares during the last quarter. Vestcor Inc purchased a new position in LivaNova during the 4th quarter worth $204,000. Finally, Optimize Financial Inc acquired a new stake in shares of LivaNova in the 4th quarter worth $208,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Price Performance

Shares of LIVN stock traded up $0.19 during trading hours on Friday, hitting $36.98. The company's stock had a trading volume of 367,986 shares, compared to its average volume of 613,364. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $64.48. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of 88.26 and a beta of 0.90. The business has a fifty day moving average of $38.07 and a 200-day moving average of $45.75.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on LIVN shares. Barclays cut their price target on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a report on Friday, March 7th. Mizuho decreased their price target on LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group cut their price objective on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. StockNews.com upgraded shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 25th. Finally, Needham & Company LLC reissued a "buy" rating and set a $64.00 price objective on shares of LivaNova in a report on Monday, March 17th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $61.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.